Oct. 25, 2013
/PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has priced an underwritten public offering of 4,375,000 shares of its common stock at an offering price of
per share, for total gross proceeds (before underwriting discount and commissions and estimated expenses) of approximately
. The Company has granted the underwriters a 30-day option to purchase up to 656,250 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on
October 30, 2013
, subject to customary closing conditions.
The Company plans to use the net proceeds of the offering, together with other available funds, to progress the clinical development programs for its drug candidates, Pracinostat, ME-344 and PWT143, and for other general corporate purposes.
Stifel and Cowen and Company are acting as joint book-runners for the offering. Wedbush PacGrow Life Sciences and Roth Capital Partners are acting as co-managers.
The securities described above are being offered pursuant to a "shelf" registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). The offering is being made only by means of a prospectus supplement and accompanying base prospectus. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate,
One Montgomery Street
, Suite 3700,
San Francisco, California
94104, or by calling (415) 364-2500, or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, New York
11717, Attention: Prospectus Department, or by calling (631) 274-2806, or by faxing (631) 254-7140. An electronic copy of the prospectus supplement and accompanying base prospectus relating to the offering will also be available on the website of the SEC at
This release does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.